From our proprietary biomarkers, our innovated assays solutions, our unique data analysis platforms and our CDx development capabilities, we offer a comprehensive family of biomarker services that enhance your insight into the tumor microenvironment (TME).
With Immunosign®, clinical researchers can conduct pre- and post-treatment immune monitoring to understand the functional orientation of immune cells and the naturally-occuring intra-tumor immune response.
Immunosign® is available in two predictive and prognostic gene signature panels that provide non-overlapping information on adaptive immunity and immune suppression. The assay is run on the Nanostring platform and can be used with or without the 770 gene nCounter® PanCancer Immune Profiling Panel.
Immunosign® includes categorization of patients into “high” and “low” Immunosign® scores, which are assigned by applying our proprietary algorithms to the Immunosign® gene signatures. The Immunosign® score translates the gene signature analysis into actionable information for patient stratification and deeper insights into treatment impact.